Comparison of the effectiveness of antibody and cell-mediated immunity against inhaled and instilled influenza virus challenge

Virology Journal

Maryna C Eichelberger³  J Kyle Bohannon²  John E Trombley²  Kevin Yang³  Jin Gao³  Larry E Bowen¹  Katie Rivers³ 

[1] Current address: Alion Science and Technology, NIEHS Inhalation Toxicology Facility, 5 Triangle Drive, P.O. Box 12313, Durham, NC 27709, USA;Southern Research Institute, Birmingham, AL 35205, USA;Division of Viral Products, OVRR, CBER, FDA, 8800 Rockville Pike, Building 29A 1D24, Bethesda, MD 20892, USA

关键词: Immunity;    CD8+ T cell;    Antibody;    Mouse;    Instillation;    Inhalation;    Aerosol;    Influenza;   

Others  :  1149495
DOI  :  10.1186/1743-422X-10-198

 received in 2013-02-09, accepted in 2013-06-11,  发布年份 2013

【 摘 要 】

Background

To evaluate immunity against influenza, mouse challenge studies are typically performed by intranasal instillation of a virus suspension to anesthetized animals. This results in an unnatural environment in the lower respiratory tract during infection, and therefore there is some concern that immune mechanisms identified in this model may not reflect those that protect against infectious virus particles delivered directly to the lower respiratory tract as an aerosol.

Method

To evaluate differences in protection against instilled and inhaled virus, mice were immunized with influenza antigens known to induce antibody or cell-mediated responses and then challenged with 100 LD₅₀ A/PR/8/34 (PR8) in the form of aerosol (inhaled) or liquid suspension (instilled).

Results

Mice immunized with recombinant adenovirus (Ad) expressing hemagglutinin were protected against weight loss and death in both challenge models, however immunization with Ad expressing nucleoprotein of influenza A (NP_A) or M2 resulted in greater protection against inhaled aerosolized virus than virus instilled in liquid suspension. Ad-M2, but not Ad-NP_A-immunized mice were protected against a lower instillation challenge dose.

Conclusions

These results demonstrate differences in protection that are dependent on challenge method, and suggest that cell-mediated immunity may be more accurately demonstrated in mouse inhalation studies. Furthermore, the data suggest immune mechanisms generally characterized as incomplete or weak in mouse models using liquid intranasal challenge may offer greater immunity against influenza infection than previously thought.

【 授权许可】

   
2013 Rivers et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Dushoff J, Plotkin J, Viboud C, Earn DJD, Simonsen L: Mortality due to influenza in the United States–an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006, 163:181-187.
• [2]Osterholm MT: Preparing for the next pandemic. N Engl J Med 2005, 352:1839-1842.
• [3]Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Nino D, Belmont JW: Antibody correlates and predictors of immunity to naturally-occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013, 207:974-981.
• [4]Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
• [5]Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ: Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5404-5410.
• [6]Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL: Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 2010, 5:e13162.
• [7]Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL: Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27:6512-6521.
• [8]Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, Perez DR, Ye J, Tompkins SM, Epstein SL: Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 2011, 6:e21937.
• [9]Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL: Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13:426-435.
• [10]Jegerlehner A, Schmitz N, Storni T, Bachmann MF: Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
• [11]Stein-Streilein J, Bennett M, Mann D, Kumar V: Natural killer cells in mouse lung: surface phenotype, target preference, and response to local influenza virus infection. J Immunol 1983, 131:2699-2704.
• [12]Ely KH, Cookenham T, Roberts AD, Woodland DL: Memory T cell populations in the lung airways are maintained by continual recruitment. J Immunol 2006, 176:537-543.
• [13]Morris MA, Ley K: Trafficking of natural killer cells. Curr Mol Med 2004, 4:431-438.
• [14]Verbist KC, Cole CJ, Field MB, Klonowski KD: A role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection. J Immuno 2011, 186:174-182.
• [15]Eichelberger MC, Green MD: Animal models to assess the toxicity, immunogenicity and effectiveness of candidate influenza vaccines. Expert Opin Drug Metab Toxicol 2011, 7:1117-1127.
• [16]Tripp RA, Tompkins SM: Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 2009, 333:397-412.
• [17]Bodewes R, Rimmelzwaan GF, Osterhaus AD: Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 2010, 9:59-72.
• [18]Jefferson T, Foxlee R, Del Mar C, Dooley L, Ferroni E, Hewak B, Prabhala A, Nair S, Rivetti A: Interventions for the interruption or reduction of the spread of respiratory viruses. Cochrane Rev J Evidence-based Child Health 2008, 3:951-1013.
• [19]Tellier R: Review of aerosol transmission of influenza A virus. Emerg Infect Dis 2006, 12:1657-1662.
• [20]Tellier R: Aerosol transmission of influenza A virus: a review of new studies. J R Soc Interface 2009, 6(Suppl 6):S783-790.
• [21]Scott GH, Sydiskis RJ: Responses of mice immunized with influenza virus by aerosol and parenteral routes. Infect Immun 1976, 13:696-703.
• [22]Knight V: Viruses as agents of airborne contagion. Ann N Y Acad Sci 1980, 353:147-156.
• [23]Smith JH, Nagy T, Barber J, Brooks P, Tompkins SM, Tripp RA: Aerosol inoculation with a sub-lethal influenza virus leads to exacerbated morbidity and pulmonary disease pathogenesis. Viral Immunol 2011, 24:131-142.
• [24]Frankova V: Inhalatory infection of mice with influenza A0/PR8 virus. I. The site of primary virus replication and its spread in the respiratory tract. Acta Virol 1975, 19:29-34.
• [25]Lednicky JA, Hamilton SB, Tuttle RS, Sosna WA, Daniels DE, Swayne DE: Ferrets develop fatal influenza after inhaling small particle aerosols of highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1). Virol J 2010, 7:231. BioMed Central Full Text
• [26]Bowen LE, Rivers K, Trombley JE, Bohannon JK, Li SX, Boydston JA, Eichelberger MC: Development of a murine nose-only inhalation model of influenza: comparison of disease caused by instilled and inhaled A/PR/8/34. Front Cell Infect Microbiol 2012, 2:74.
• [27]Larson EW, Dominik JW, Rowberg AH, Higbee GA: Influenza virus population dynamics in the respiratory tract of experimentally infected mice. Infect Immun 1976, 13:438-447.
• [28]Misplon JA, Lo CY, Gabbard JD, Tompkins SM, Epstein SL: Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 2010, 28:5817-5827.
• [29]Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherty PC: Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 1991, 174:875-880.
• [30]Straight TM, Ottolini MG, Prince GA, Eichelberger MC: Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats. Virol J 2008, 5:44. BioMed Central Full Text
• [31]Nguyen H, Zemlin M, Ivanov I, Andrasi J, Zemlin C, Vu H, Schelonka R, Schroeder H, Mestecky J: Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire. J Virol 2007, 81:9331-9338.
• [32]Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR: Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol 1994, 68:3505-3511.
• [33]Lin YL, Askonas BA: Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J Exp Med 1981, 154:225-234.
• [34]Markovic SN, Knight PR, Murasko DM: Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. Anesthesiology 1993, 78:700-706.
• [35]Allan W, Tabi Z, Cleary A, Doherty PC: Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J Immunol 1990, 144:3980-3986.
• [36]Ottolini MG, Blanco JC, Eichelberger MC, Porter DD, Pletneva L, Richardson JY, Prince GA: The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 2005, 86:2823-2830.
• [37]Flandre TD, Leroy PL, Desmecht DJ: Effect of somatic growth, strain, and sex on double-chamber plethysmographic respiratory function values in healthy mice. J Appl Physiol 2003, 94:1129-1136.